Biogen Inc
NASDAQ: BIIB
$165.79
-$2.49 (-1.5%)
Closing Price on November 13, 2024
BIIB Articles
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Biogen, Discovery Communications, Mosaic, Plains All American, Phillips 66 and Rubicon Project.
Published:
Last Updated:
Finally, concerns about biotech seem to be waning. An RBC research report notes that at the recent political conventions there was little to no mention of drug pricing.
Published:
Last Updated:
Shares of Biogen and, especially, Ionis Pharmaceuticals made handy gains early Monday morning following favorable interim results from a late-stage trial.
Published:
Last Updated:
The short interest data are out for the July 15 settlement date. Short interest increased across many of these selected biotech stocks.
Published:
Last Updated:
The June 30 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
Published:
Last Updated:
Sometimes market volatility and outside shocks create a rift between market prices and real value. That may currently be the case in the largest stocks in the biotech sector within health care if...
Published:
Last Updated:
The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of stocks, with big potential upside and big potential downside. After all, a cure or...
Published:
Last Updated:
June 22, 2016: Here are four stocks trading with relatively heavy volume among 40 equities making new 52-week lows in Wednesday’s session. NYSE decliners led advancers by 5 to 4 while Nasdaq...
Published:
Last Updated:
Biotech companies that lost their way last week truly burned shareholders, whether it was due to ASCO, earnings or even unfavorable clinical trial updates.
Published:
Last Updated:
The May 31 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
Published:
Last Updated:
Shares of Biogen slumped early in Tuesday's session following the release of less-than-favorable top-line results from its mid-stage clinical study evaluating opicinumab.
Published:
Last Updated:
The May 13 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
Published:
Last Updated:
A new JPMorgan research report highlights some large cap secular growth stocks that have shown strong and consistent revenue growth over the past 10 years, even during the recession.
Published:
Last Updated:
The short interest data are out for the April 29 settlement date, and short interest moves were mixed in these selected biotech stocks.
Published:
Last Updated:
The April 15 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated: